Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Young-Pil Wang
Clinical Responses and Prognostic Indicators of Concurrent Chemoradiation for Non-Small Cell Lung Cancer
Cancer Research and Treatment
Cancer Research
Oncology
Prognostic Value of SUVmax and Metabolic Tumor Volume on 18f-FDG PET/CT in Early Stage Non-Small Cell Lung Cancer Patients Without LN Metastasis
Bio-Medical Materials and Engineering
Medicine
Biomaterials
Biomedical Engineering
Related publications
Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non–Small Cell Lung Cancer
American Journal of Clinical Oncology: Cancer Clinical Trials
Cancer Research
Oncology
Concurrent Chemoradiation in Elderly Patients With Limited-Stage Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Prognostic Gene Signatures for Non-Small-Cell Lung Cancer
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Quality-Of-Care Indicators for Non-Small Cell Lung Cancer
Cancer Control
Medicine
Oncology
Hematology
Prognostic Value of Neutrophil-To-Lymphocyte Ratio Following Chemoradiation Therapy for Stage III Non–small Cell Lung Cancer
International Journal of Radiation Oncology Biology Physics
Oncology
Radiology
Cancer Research
Radiation
Nuclear Medicine
Imaging
Prognostic Factors for Survival After Recurrence of Stage III Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Therapy
International Journal of Radiation Oncology Biology Physics
Oncology
Radiology
Cancer Research
Radiation
Nuclear Medicine
Imaging
Preoperative Concurrent Chemoradiotherapy for Stage IIIA Non-Small Cell Lung Cancer
Acta Oncologica
Nuclear Medicine
Radiology
Hematology
Oncology
Medicine
Imaging
Prognostic Significance of CD276 in Non-Small Cell Lung Cancer
Open Medicine (Poland)
Medicine
Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Receiving Concurrent Metformin and Immune Checkpoint Inhibitors
Lung Cancer Management